1University of Cuenca, Faculty of Medical Sciences, Medical School, Cuenca, Ecuador; and 2Department of Cardiology, Rosalind Franklin University of Medicine and Science, Chicago Medical School, North Chicago, IL.
Am J Ther. 2017 Nov/Dec;24(6):e737-e743. doi: 10.1097/MJT.0000000000000354.
Heart failure (HF) is a complex multifactorial medical condition that should be addressed according to its complexity and diversity. Currently, there is a medical arsenal available for the management of HF, but despite the advance in medical resources, its prevalence and social and financial impacts are still worrisome for the medical community and society. Among the numerous therapeutic options for the treatment of HF, neprilysin inhibitors have changed the perspective of the approach to titrate patients who suffer from this condition because neprilysin plays a role in the degradation of natriuretic peptides and various other vasoactive compounds that are crucial to counteract the devastating pathophysiology of HF. The purpose of this review was to analyze the role of neprilysin inhibitors in HF, focusing on newer therapy such as LCZ696 and studies that sustain its potential benefits in this medical entity.
心力衰竭（HF）是一种复杂的多因素医学病症，应根据其复杂性和多样性进行治疗。目前，有多种医学手段可用于 HF 的管理，但尽管医学资源有所进步，HF 的患病率及其对社会和经济的影响仍然令医学界和社会担忧。在 HF 治疗的众多治疗选择中，脑啡肽酶抑制剂改变了治疗患者的方法，因为脑啡肽酶在利钠肽和各种其他血管活性化合物的降解中发挥作用，这些化合物对于抵消 HF 的破坏性病理生理学至关重要。本综述的目的是分析脑啡肽酶抑制剂在 HF 中的作用，重点关注 LCZ696 等新型治疗方法以及支持其在该医学实体中潜在益处的研究。
